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underwent breast reduction (5 PRINEO* and 5 SOC). Data were collected for surgery 
through post-op care. Data Observation Forms were designed based on information 
obtained from staff interviews. Activities were observed for which differences in time 
and supplies between PRINEO* and SOC were expected: incision closure, dressing 
application, and dressing changes. RESULTS: In Germany, average time for skin layer 
closure was 3.47 min with PRINEO* vs. 16.67 min for SOC. Average wound length 
was 57 cm vs. 54 cm, respectively, translating into higher speed of closure with 
PRINEO* (16.50 cm/min) compared to SOC (3.22 cm/min). Overall time for wound 
closure was similar in both arms due to increased time for dermal layer closure with 
PRINEO* (42 min). In the Netherlands, average time for skin layer closure was 
1.57 min for PRINEO* vs. 15.83 min for SOC. Average wound length was 48 cm vs. 
49 cm, respectively, translating into a speed of closure with PRINEO* of 30.74 cm/
min compared to 3.11 cm/min with SOC. Time for dermal and skin layer closure 
combined was lower for PRINEO* (13.47 min vs. 29.93 min). For dressing applica-
tion and post-op dressing changes, SOC required on average 18.28 min in Germany 
and 3.95 min in the Netherlands. Additionally, the use of 1.2 PRINEO* units on 
average resulted in the elimination of sutures and dressings in both centres. CONCLU-
SIONS: In one German and Dutch centre, the use of PRINEO* lead to increased skin 
closure speed and avoided time and supplies associated with dressing application and 
changes, at the expense of an average 1.2 PRINEO* units.
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OBJECTIVES: Among the two most frequently prescribed forms of vaginal estrogen 
(VE), acceptability of tablets has been shown to be greater than creams in clinical 
trials. However, creams are more often prescribed. This study examines the association 
between form of VE and initial prescription reﬁll rate and treatment duration among 
Medicaid enrollees. METHODS: A retrospective cohort study was conducted using 
North Carolina Medicaid claims January 2003 to December 2007 of women ages 
18–64 with a new VE prescription claim. Multiple logistic regression was performed 
to assess the association of VE form and initial prescription reﬁll among women with 
1 year post-index continuous enrollment; OLS regression was used to assess treatment 
duration over 2 years follow-up. Demographic factors included age and race. Addi-
tional covariates: Charlson-Deyo comorbidity index, number of outpatient visits, 
mammography, and systemic estrogen use in the pretreatment year, and index year. 
RESULTS: A total of 1812 patients prescribed VE (mean age 49.4 o 10.5, 30.9% 
black) having 1 year follow-up were identiﬁed; 465 women had 2 years follow-up. 
89.6% received cream; 10.4% tablets. Initial prescription reﬁll rate was 48.7% for 
tablets, 33.7% for cream (p  0.001). Average treatment duration among women 
with 1 reﬁll and 2 years follow-up was longer for tablets than cream (291.7 o 214.3 
days versus 281.8 o 226.3; p  0.745). Tablet users were signiﬁcantly more likely to 
reﬁll their initial prescription (OR 1.88, 95%CI  1.38–2.56). OLS regression results 
showed no signiﬁcant difference in treatment duration for tablets vs. cream (beta  
17.53, 95%CI  42.56–77.62). CONCLUSIONS: This analysis of Medicaid claims 
showed tablet users were signiﬁcantly more likely to reﬁll their initial prescription than 
cream users. During 2 years of follow-up, treatment duration among those who reﬁlled 
at least once was longer for tablet users, although not signiﬁcant. These results give 
some real world support for women’s greater acceptability of vaginal tablets to 
creams.
PIH27
HEALTH RELATED QUALITY OF LIFE AND UTILITY SCORES IN 
MENOPAUSAL WOMEN
Iskedjian M1, Shapiro M2, Wang M3, Farah B4, Walker J1
1PharmIdeas Research and Consulting Inc, Oakville, ON, Canada, 2University of Toronto, 
Toronto, ON, Canada, 3Wyeth Pharmaceuticals, Markham, ON, Canada, 4PharmIdeas 
Research and Consulting Inc, Ottawa, ON, Canada
OBJECTIVES: A study was performed to determine quality of life (QoL) and utility 
scores associated with 3 stages of menopause: pre-menopause, perimenopause and 
post-menopause. METHODS: A cross-sectional study was conducted in Canada to 
determine the quality of life and utility scores associated with each stage of menopause 
as listed above. Women age 48–54 were recruited through primary care practices. The 
Menopause-Speciﬁc Quality of Life Questionnaire (MENQOL), a non-preference-
based QoL measure, included 29 items from 4 domains. Two preference-based tools 
were applied: Health Utilities Index Mark-3 (HUI-3) with 8 domains as an indirect 
measure of utility and a visual analogue scale (VAS) as a direct measure of disutility 
for menopausal symptoms. Mean and standard deviations (SD) were reported. Spear-
man’s-rho test was applied for correlation between the various tools. Multiple regres-
sion analyses were performed to assess if demographic characteristics predicted scores 
on any of the measures, including individual MENQOL symptom scores. RESULTS: 
A total of 403 female subjects were recruited from 11 primary care practices in 4 
provinces; 60% were employed and 63% had completed college. The mean MENQOL 
symptom scores ranged 3.1(SD  2.0) to 3.4(SD  2.1) out of 8. Speciﬁc MENQOL 
scores ranged 2.1–2.7, 3.0–3.6 and 3.4–3.9 for pre-, peri- and post-menopause respec-
tively. HUI-3 scores were 0.83, 0.78 and 0.74 for the same sequence [overall 0.77 (SD 
 0.25)], and disutility scores with the VAS were 0.22, 0.37 and 0.37. The MENQOL 
vasomotor, psychological, physical and sexual domain scores correlated signiﬁcantly 
with both VAS and HUI-3 scores (p  0.001). Some demographic variables were 
associated with certain domains of the MENQOL or the HUI-3; however, no signiﬁ-
cant associations were noted for age or education. Signiﬁcant differences existed in 
utility scores between pre- and post-menopause. CONCLUSIONS: Of the three meno-
pause subgroups investigated, the pre-menopause group was associated with the best 
QoL; QoL did not differ signiﬁcantly between peri- and post-menopause.
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OBJECTIVES: Endometriosis is a common, chronic gynaecological disease among 
women of reproductive age. Understanding treatment effects for endometriosis is 
critical for beneﬁtting the health of women with this condition. The SF-36 has utility 
for understanding this condition because of some of its subscale focus (pain) and its 
ability to compare across diseases and populations. The SF-36 is one of the most 
common health measures used in studies of endometriosis; however, it has not been 
validated for this disease. The goal of this study was to assess validity of the SF-36 
for endometriosis. METHODS: Using data from two clinical trials (N  252 & 198) 
of treatment for endometriosis, a full complement of psychometric analyses was per-
formed. Additional instruments included a pelvic pain VAS and a clinical global 
impression of change (CGI-C). Analyses were conducted using Stata 10.1 and Mplus 
5.1. RESULTS: Factor analyses conﬁrmed the standard 8-subscale and 2-component 
factor structure of the SF-36 (CFI  0.94 and 0.93 for the two trials). The Bodily Pain 
(BP) subscale and the PCS were both moderately correlated with the pain VAS 
at baseline and over time (r  0.37 to 0.62; p  0.001). Change in BP and PCS 
 correlated with the CGI-C (r  0.30 & 0.43; p  0.001): those who had the 
greatest change in BP and PCS also reported the greatest change on CGI-C. Other 
subscales (Role Physical, General Health, Vitality, Social Functioning) showed smaller 
correlations with change in the pain VAS and CGI-C. CONCLUSIONS: The SF-36 
–particularly BP and the PCS—is sensitive to differences in patient pain and change 
in pain experience in endometriosis. The BP subscale and the PCS were dimensions 
of the SF-36 that showed consistent sensitivity to pain differences and change; 
however, other SF-36 subscales were signiﬁcantly, but less strongly, related to 
differences in severity and changes in pain.
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OBJECTIVES: The Eyelash Satisfaction Questionnaire (ESQ) has demonstrated its 
validity among adults in the US, but cross-national equivalence has not been docu-
mented. This study was conducted to examine the face and content validity and psy-
chometric properties of the ESQ in an English speaking country in Europe, as well as 
to determine the cross-national equivalence. METHODS: Two focus groups (n  16) 
were conducted in the UK to examine the validity of the conceptual framework, as 
well as face and content validity, of the ESQ. Classical Test Theory (CTT) and latent 
variable modeling techniques were performed using data collected from the web survey 
in the UK. Conﬁrmatory Factor Analysis (CFA), Multiple Group Structural Equation 
Modeling (MG-SEM), and Differential Item Functioning (DIF) were performed to 
examine the accuracy and stability of the three domains between US (n  909) and 
UK samples (n  605). RESULTS: Qualitative analysis of the focus group discussions 
supported the face and content validity of the ESQ and indicated that the conceptual 
framework established in the UK was similar to the framework established in the US. 
Internal consistency was found to be high across all three domains (Cronbach’s A  
0.90, 0.91, 0.77) and item-to-domain correlations were high (0.55–0.84). The factor 
structure found in the original survey ﬁt the data well with factor loadings ranging 
from 0.64 to 93. Measurement invariance models provided good ﬁt to the data (NNFI 
 0.97, RMSEA  0.04). No signiﬁcant DIF was found between the two samples 
(p’s  0.05) and effect sizes of the differences were small (Cohen’s d’s  0.10). CON-
CLUSIONS: The current research ﬁndings suggest that the ESQ has appropriate face 
and content validity and psychometric properties for use in the UK. It also provides 
support for the cross-national equivalence of the ESQ.
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OBJECTIVES: To investigate the symptoms and impact associated with premenstrual 
dysphoric disorder (PMDD), and the appropriateness of the patient-reported Daily 
Record of Severity of Problems (DRSP) as an instrument to assess PMDD. METHODS: 
A review of 47 published peer-review articles and conference presentations was con-
ducted to aid the development of a PMDD conceptual model. The content of the DRSP 
was then compared to the conceptual model to assess face and content validity. The 
